Trial to Assess the Efficacy and Safety of LEO 152020 in Adult Patients With Cholinergic Urticaria

Main Inclusion Criteria: * Subject with a history of Cholinergic urticaria diagnosis for ≥ 6 months * Subject has active and uncontrolled Cholinergic urticaria disease at the time of screening and randomisation, as defined by the following: 1. Urticaria control test \< 12 at screening 2. Urticaria Activity Score post-provocation ≥ 3 * Recent history (within 6 months of screening) with documented inadequate response to standard dose as to marketing authorization of H1 antihistamines. Main Exclusion Criteria: * Other clearly dominating forms\* of urticaria as aetiology for wheal and flare type reactions \*These diseases are allowed as comorbidities, if cholinergic urticaria is the dominating form of chronic urticaria, * Systemic immunosuppressive medications within 4 weeks prior to screening, * Systemic drugs (e.g. oral drug) with antihistamine properties including H1 antihistamines and some antidepressants (e.g. tricyclic antidepressants) and H2 antihistamines 1 week prior to randomisation and throughout the trial. However, topical antihistamines in the form of nasal spray and eyedrops are allowed in the standard prescribed dose.